Motzer, R. J., Braun, D. A., Powles, T., Gurney, H., Fong, L., George, D. J., Haas, N. B., McDermott, D. F., Shuch, B. M., Meehan, R., Posadas, T., Wu, S., Elfiky, A., Choueiri, T. K. (2025). INTerpath-004: A phase 2, randomized, double-blind study of adjuvant pembrolizumab (pembro) with V940 (mRNA-4157) or placebo for renal cell carcinoma (RCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps610